Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) is an indication for drug development with over 100 pipeline drugs currently active. According to GlobalData, preregistered drugs for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) overview
Chronic myeloid leukemia (CML), also known as chronic myelocytic leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age, and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen, and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation, and chemotherapy.
For a complete picture of PTSR and LoA scores for drugs in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
